Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aldeyra Therapeutics ( (ALDX) ) has issued an announcement.
On December 23, 2025, Aldeyra Therapeutics announced that Chief Development Officer Stephen G. Machatha, Ph.D., had voluntarily resigned to pursue other professional opportunities, with his last day to occur on or before March 31, 2026. Under a transition agreement signed the same day, Machatha will remain through the transition period to ensure a smooth handover of responsibilities, continuing to receive his current salary, benefits, and equity vesting, and becoming eligible for up to $176,000 in lump-sum bonus-related payments tied to his 2025 bonus, subject to releases of claims. The company emphasized that his departure was not related to any disagreement over operations, policies, or financial reporting, suggesting that the leadership change is not expected to signal operational or accounting concerns for stakeholders.
The most recent analyst rating on (ALDX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses, and heavy cash burn with declining equity). Technicals are only moderately supportive with neutral momentum, and valuation lacks support due to negative earnings. Corporate events are mixed, with encouraging clinical progress offset by a negative regulatory timeline delay.
To see Spark’s full report on ALDX stock, click here.
More about Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies, including small-molecule drugs, for immune-mediated and inflammatory diseases, with a particular emphasis on conditions with unmet medical need in ophthalmology and systemic inflammation.
Average Trading Volume: 976,995
Technical Sentiment Signal: Hold
Current Market Cap: $311M
See more insights into ALDX stock on TipRanks’ Stock Analysis page.